NewLink Genetics, an US based biotech, which focuses on discovering, developing, and commercializing novel immunotherapeutics, announced that they have entered into an exclusive worldwide license agreement with Genentech, a member of the Roche Group for the development of NLG919, NewLink’s IDO pathway inhibitor. According to the press release, the parties have also entered into a research collaboration for the discovery of next generation IDO/TDO compounds.
NewLink will receive an upfront payment of $150 million and will be eligible to receive in excess of $1 billion in milestone payments based on achievement of certain milestones as well as escalating double-digit royalties on potential commercial sales. Genentech will fund future research, development, manufacturing plus commercialization costs and it will provide research funding.
The complete press release of NewLink Genetics
News article by FierceBiotech